Peritumoral CpG Oligodeoxynucleotide Treatment Inhibits Tumor Growth and Metastasis of B16F10 Melanoma Cells
- 1 August 2004
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 123 (2), 395-402
- https://doi.org/10.1111/j.0022-202x.2004.23233.x
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Vaccination with Tumor Peptide in CpG Adjuvant Protects Via IFN-γ-Dependent CD4 Cell ImmunityThe Journal of Immunology, 2002
- Subsets of Human Dendritic Cell Precursors Express Different Toll-like Receptors and Respond to Different Microbial AntigensThe Journal of Experimental Medicine, 2001
- Bacterial CpG-DNA Triggers Activation and Maturation of Human CD11c−, CD123+ Dendritic CellsThe Journal of Immunology, 2001
- CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutansVaccine, 2000
- Bacterial DNA causes septic shockNature, 1997
- Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunityNature Medicine, 1995
- CpG motifs in bacterial DNA trigger direct B-cell activationNature, 1995
- Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2JNCI Journal of the National Cancer Institute, 1994
- Treatment of Metastatic Malignant Melanoma with Dacarbazine plus TamoxifenNew England Journal of Medicine, 1992
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987